Research programme: beta-lactam/beta-lactamase inhibitor combinations - Merck

Drug Profile

Research programme: beta-lactam/beta-lactamase inhibitor combinations - Merck

Alternative Names: 6-Alkylidenepenam sulfones - Merck; Carbapenem/beta-lactamase inhibitors - Merck; Imipenem/M 478; Imipenem/M 704; M 478; M 704

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Class Depsipeptides; Glycopeptides; Lipopeptides; Penems
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Gram-negative infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-negative-infections in USA
  • 19 Sep 2011 Antimicrobial data from early research in Gram negative infections presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2011),
  • 15 Sep 2009 Preclinical trials in Gram-negative infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top